leflunomide has been researched along with Libman-Sacks Disease in 29 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mycophenolate and leflunomide are teratogenic drugs and should be withdrawn before conception in case of programmed pregnancy or should be rapidly discontinued in case of unexpected pregnancy." | 4.91 | Immunosuppression in pregnant women with systemic lupus erythematosus. ( Moroni, G; Ponticelli, C, 2015) |
| " The earlier use of methotrexate and the introduction of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis have changed the natural characteristics of the disease." | 4.87 | [Systemic autoimmune disorders and pregnancy]. ( Kiss, CG; Kiss, E; Poór, G, 2011) |
| "Twelve systemic lupus erythematosus (SLE) patients with mild to moderate disease activity (SLEDAI of > or = 6 and on prednisolone < 0." | 2.71 | Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. ( Lam, CW; Li, EK; Szeto, CC; Tam, LS; Wong, CK, 2004) |
| "These included systemic lupus erythematosus disease activity index (SLEDAI) score, serum albumin (Alb), 24‑h urinary protein, serum creatinine, anti‑ds‑DNAIgM, complement component 3 (C3), and the number of effective treatments and complications." | 2.66 | Effectiveness of Bailing capsules in the treatment of lupus nephritis: A meta‑analysis. ( Bi, C; Li, Y; Qiu, X; Tian, B; Xu, T; Yao, L, 2020) |
| "Leflunomide is a new immunosuppressive medicine that has been effectively used in the therapy of rheumatoid arthritis and subsequently used with success in animal models and patients with systemic lupus erythematosus (SLE)." | 2.49 | Leflunomide: friend or foe for systemic lupus erythematosus? ( Huang, Q; Wu, GC; Wu, H; Xu, XD, 2013) |
| "Arthritis in systemic lupus erythematosus (SLE) is episodic and self-limited in most patients." | 2.48 | How to treat refractory arthritis in lupus? ( Artifoni, M; Puéchal, X, 2012) |
| "A total of 1069 adult systemic lupus erythematosus (SLE) patients who were hospitalized for the first time in 26 hospitals in Jiangsu Province from 1999 to 2009 were retrospectively analyzed." | 1.72 | Predictors of improvement in disease activity in first hospitalized patients with systemic lupus erythematosus: a multicenter retrospective study of a Chinese cohort. ( Da, Z; Ding, F; Ding, X; Feng, X; Hu, H; Li, J; Li, M; Liang, J; Liu, L; Pan, W; Qian, X; Sun, L; Tan, J; Tao, J; Wang, M; Wei, H; Wen, L; Wu, J; Wu, M; Zhang, H; Zhang, M; Zou, Y, 2022) |
| "Based on a pharmacokinetic (PK) study assessing the relative bioavailability of teriflunomide sodium compared to leflunomide, a population pharmacokinetic (Pop PK) analysis was firstly conducted using non-linear mixed effect model." | 1.51 | A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus. ( Chen, X; Hu, P; Jiang, J; Liu, D; Wu, Y; Yao, X, 2019) |
| "Episcleritis and scleritis are relatively rare ocular diseases, which are commonly associated with rheumatic diseases including systemic lupus erythematosus (SLE)." | 1.43 | [Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus]. ( Jia, Y; Miao, H; Wang, L; Yang, Y; Zhang, XY; Zhou, YS, 2016) |
| "Four months later widespread prunosus skin rash appeared on her skin." | 1.35 | Severe cutaneous adverse drug reaction to leflunomide: a report of two cases. ( Guo, G; Jian, X; Li, X; Lin, D; Ruan, Y, 2008) |
| "Leflunomide was efficacious and safe in this cohort of SLE patients after 2-3 months of therapy." | 1.31 | Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. ( Remer, CF; Wallace, DJ; Weisman, MH, 2001) |
| "Leflunomide is an antirheumatic drug." | 1.31 | [Leflunomide in systemic lupus erythematosus]. ( Kessel, A; Toubi, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.90) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (37.93) | 29.6817 |
| 2010's | 12 (41.38) | 24.3611 |
| 2020's | 4 (13.79) | 2.80 |
| Authors | Studies |
|---|---|
| Carrión-Barberà, I | 1 |
| Polino, L | 1 |
| Mejía-Torres, M | 1 |
| Pérez-García, C | 1 |
| Ciria, M | 1 |
| Pros, A | 1 |
| Rodríguez-García, E | 1 |
| Monfort, J | 1 |
| Salman-Monte, TC | 1 |
| Li, M | 1 |
| Liang, J | 1 |
| Pan, W | 1 |
| Liu, L | 1 |
| Wu, M | 1 |
| Ding, F | 1 |
| Hu, H | 2 |
| Ding, X | 1 |
| Wei, H | 1 |
| Zou, Y | 1 |
| Qian, X | 1 |
| Wang, M | 1 |
| Wu, J | 1 |
| Tao, J | 1 |
| Tan, J | 1 |
| Da, Z | 1 |
| Zhang, M | 1 |
| Li, J | 1 |
| Feng, X | 1 |
| Wen, L | 1 |
| Zhang, H | 1 |
| Sun, L | 1 |
| Hu, YQ | 1 |
| Mu, ZL | 1 |
| Zhang, JZ | 1 |
| Li, Y | 1 |
| Xu, T | 1 |
| Qiu, X | 1 |
| Tian, B | 1 |
| Bi, C | 1 |
| Yao, L | 1 |
| Zhou, QS | 1 |
| Hu, J | 1 |
| Yao, X | 1 |
| Wu, Y | 1 |
| Jiang, J | 1 |
| Chen, X | 1 |
| Liu, D | 1 |
| Hu, P | 1 |
| Oliveira, AC | 1 |
| Mota, LM | 1 |
| Santos-Neto, LL | 1 |
| Simões, M | 1 |
| Martins-Filho, OA | 1 |
| Tauil, PL | 1 |
| Cortés-Hernández, J | 1 |
| Egri, N | 1 |
| Vilardell-Tarrés, M | 1 |
| Ordi-Ros, J | 1 |
| Ponticelli, C | 1 |
| Moroni, G | 1 |
| Dong, GF | 2 |
| Zhang, X | 2 |
| He, DN | 1 |
| Li, L | 1 |
| Zhang, GF | 1 |
| Elera-Fitzcarrald, C | 1 |
| Alfaro-Lozano, JL | 1 |
| Pastor-Asurza, CA | 1 |
| Wang, L | 1 |
| Yang, Y | 1 |
| Jia, Y | 1 |
| Miao, H | 1 |
| Zhou, YS | 1 |
| Zhang, XY | 1 |
| Lu, MC | 1 |
| Yu, CL | 1 |
| Yin, WY | 1 |
| Tung, CH | 1 |
| Huang, KY | 1 |
| Liu, SQ | 1 |
| Lai, NS | 1 |
| Kiss, E | 1 |
| Kiss, CG | 1 |
| Poór, G | 1 |
| Palazzo, E | 1 |
| Yahia, SA | 1 |
| Artifoni, M | 1 |
| Puéchal, X | 1 |
| Wu, GC | 1 |
| Xu, XD | 1 |
| Huang, Q | 1 |
| Wu, H | 1 |
| Takeuchi, T | 1 |
| Amano, K | 1 |
| Tsuzake, K | 1 |
| Kameda, H | 1 |
| Abe, T | 1 |
| Tam, LS | 1 |
| Li, EK | 1 |
| Wong, CK | 1 |
| Lam, CW | 1 |
| Szeto, CC | 1 |
| Zhou, H | 1 |
| Shi, YZ | 1 |
| van Woerkom, JM | 1 |
| Kruize, AA | 1 |
| Geenen, R | 1 |
| van Roon, EN | 1 |
| Goldschmeding, R | 1 |
| Verstappen, SM | 1 |
| van Roon, JA | 1 |
| Bijlsma, JW | 1 |
| Jian, X | 1 |
| Guo, G | 1 |
| Ruan, Y | 1 |
| Lin, D | 1 |
| Li, X | 1 |
| Remer, CF | 1 |
| Weisman, MH | 1 |
| Wallace, DJ | 1 |
| Barthel, HR | 1 |
| Wallace, D | 1 |
| Abu-Shakra, M | 1 |
| Buskila, D | 1 |
| Kessel, A | 1 |
| Toubi, E | 1 |
| Popovic, S | 2 |
| Bartlett, RR | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Importance of Therapeutic Monitoring of Orally Administered Disease-modifying Drugs Used in the Treatment of Multiple Sclerosis[NCT05112484] | 600 participants (Anticipated) | Observational | 2023-10-01 | Not yet recruiting | |||
| Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area[NCT03430388] | 600 participants (Actual) | Interventional | 2018-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for leflunomide and Libman-Sacks Disease
| Article | Year |
|---|---|
Effectiveness of Bailing capsules in the treatment of lupus nephritis: A meta‑analysis.
Topics: Complement C3; Creatinine; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Leflunomide; Lu | 2020 |
Immunosuppression in pregnant women with systemic lupus erythematosus.
Topics: Contraindications; Cyclosporine; Female; Glucocorticoids; Humans; Hypertension; Immunosuppression Th | 2015 |
[Systemic autoimmune disorders and pregnancy].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antimalarials; Antiphospholipid Syndrome; Arthrit | 2011 |
Progressive multifocal leukoencephalopathy in autoimmune diseases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rhe | 2012 |
How to treat refractory arthritis in lupus?
Topics: Abatacept; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2012 |
Leflunomide: friend or foe for systemic lupus erythematosus?
Topics: Animals; Autoimmunity; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lupus Erythematosu | 2013 |
[Collagen diseases and rheumatic diseases].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmunity; Drug Therapy, Com | 2004 |
Current and emerging lupus treatments.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Dehydroepiandroster | 2001 |
3 trials available for leflunomide and Libman-Sacks Disease
| Article | Year |
|---|---|
Analysis of changes in joint function and peripheral blood mononuclear cells in patients with systemic lupus erythematosus and intervention effects of different drugs.
Topics: Adult; Aged; Chemokine CXCL10; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Isoxazole | 2017 |
Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus.
Topics: Adult; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lupus | 2004 |
Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.
Topics: Adult; Aniline Compounds; Crotonates; Diarrhea; Facial Dermatoses; Fatigue; Female; Humans; Hydroxyb | 2007 |
18 other studies available for leflunomide and Libman-Sacks Disease
| Article | Year |
|---|---|
Leflunomide: A safe and effective alternative in systemic lupus erythematosus.
Topics: Humans; Immunosuppressive Agents; Leflunomide; Lupus Erythematosus, Systemic | 2022 |
Predictors of improvement in disease activity in first hospitalized patients with systemic lupus erythematosus: a multicenter retrospective study of a Chinese cohort.
Topics: Adult; Antibodies, Antinuclear; C-Reactive Protein; China; Creatinine; Humans; Leflunomide; Lupus Er | 2022 |
Erythema multiforme-like drug eruption in a patient with systemic lupus erythematosus treated with leflunomide.
Topics: Drug Eruptions; Erythema Multiforme; Humans; Leflunomide; Lupus Erythematosus, Systemic | 2020 |
A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus.
Topics: Arthritis, Rheumatoid; ATP Binding Cassette Transporter, Subfamily G, Member 2; Body Weight; Crotona | 2019 |
Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumat | 2015 |
Etanercept in refractory lupus arthritis: An observational study.
Topics: Adult; Antirheumatic Agents; Arthritis; Autoantibodies; Cohort Studies; Etanercept; Female; Glucocor | 2015 |
Effect of Leflunomide on the Abnormal Expression of Lipid Rafts and F-Actin in B Lymphocytes from Patients with Systemic Lupus Erythematosus.
Topics: Actins; Adult; Aniline Compounds; Antigens, CD; B-Lymphocytes; Case-Control Studies; Crotonates; Fem | 2015 |
Garre's sclerosing osteomyelitis caused by salmonella group D in a patient with systemic lupus erythematosus: an unusual complication.
Topics: Adult; Anti-Bacterial Agents; Antiphospholipid Syndrome; Ceftazidime; Doxycycline; Femur; Humans; Hy | 2015 |
[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinucle | 2016 |
Increased prevalence of polyomavirus BK viruria that correlates with thrombocytopenia in patients with systemic lupus erythematosus on intensive immunosuppressive therapy.
Topics: Adult; Antiviral Agents; BK Virus; Female; Humans; Immunosuppression Therapy; Isoxazoles; Leflunomid | 2009 |
[An exploratory study on in vitro effects and mechanism of leflunomide on dendritic cells of systemic lupus erythematosus].
Topics: Adolescent; Adult; Cell Proliferation; Cells, Cultured; Dendritic Cells; Female; Flow Cytometry; Hum | 2005 |
Severe cutaneous adverse drug reaction to leflunomide: a report of two cases.
Topics: Adolescent; Anti-Inflammatory Agents; Blister; Drug Eruptions; Exanthema; Female; Glucocorticoids; H | 2008 |
Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study.
Topics: Adult; Blood Sedimentation; Cyclosporine; Female; Humans; Isoxazoles; Leflunomide; Lupus Erythematos | 2001 |
Leflunomide for the treatment of systemic lupus erythematosus: comment on the article by McMurray.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Female; Humans; Hydroxychloroqui | 2001 |
Update on the treatment of systemic lupus erythematosus: therapeutic highlights from the Sixth International Lupus Conference.
Topics: Antimalarials; Biological Therapy; Congresses as Topic; Cyclophosphamide; Dehydroepiandrosterone; He | 2002 |
[Leflunomide in systemic lupus erythematosus].
Topics: Adult; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lupus Erythematosus, Syste | 2002 |
The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery.
Topics: Animals; Cyclophosphamide; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Graft vs Ho | 1987 |
Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Isoxazoles; Leflunomide; Lupus Erythematosus | 1986 |